Tests CTI-1601 long term in people with Friedreich's ataxia
Studies the long-term safety of daily CTI-1601 in people with Friedreich's ataxia.
Plain-language title generated from the registry record
Registry title: An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Key facts
- Where
- Chevy Chase, Columbus, Eatontown, Gainesville, Iowa City, Los Angeles, Philadelphia, Salt Lake City, San Francisco, and Tampa, United StatesSee the 10 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 60 years old?
Source: NCT06447025, who can take part
Where in United States
- Uncommon CuresChevy Chase, United StatesTaking people
- Ohio State University Wexner Medical CenterColumbus, United StatesNo longer taking part
- Clinilabs Drug Development, Corp.Eatontown, United StatesTaking people
- Fixel Institute for Neurological Disease, University of Florida HealthGainesville, United StatesNo longer taking part
- University of Iowa Hospitals & ClinicsIowa City, United StatesTaking people
- University of California, Los AngelesLos Angeles, United StatesNo longer taking part
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesTaking people
- ICONSalt Lake City, United StatesTaking people
- University of California, San Franciso Medical CenterSan Francisco, United StatesTaking people
- Morsani Center for Advanced Health Care, University of South Florida HealthTampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Larimar Therapeutics, Inc.
- Trial code
- NCT06447025
- Record updated
- 27 October 2026
- Original description
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.Read full original descriptionShow less
An Open-Label Extension Study to Assess the Long-Term Safety, Efficacy, Pharmacodynamics, Pharmacokinetics, and Tolerability of Subcutaneous CTI-1601 in Subjects With Friedreich's Ataxia
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.
Inclusion: Subjects with FRDA who have or have not previously completed participation in a study of CTI-1601 are eligible to participate in this study unless the subject experienced one or more of the following in a previous CTI-1601 study: a) serious adverse event (SAE) related to study drug; b) significant AE, defined as Grade 3 or higher according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (or higher), related to study drug; c) some other event, related to participation in a previous study with CTI-1601, that supports the exclusion of the subject from participating in this study as determined by the Sponsor (i.e., an AE considered clinically significant by the Sponsor regardless of whether it met SAE criteria and regardless of CTCAE grade); d) Withdraw from participation in a previous study of CTI-1601 for any reason; Subject has a HbA1c less than or equal to 7.0%; Subject must demonstrate sufficient dexterity and visual acuity to prepare and self-administer SC injections of CTI-1601 QD or is able to identify a caregiver who will be trained and committed to prepare and administer the daily injections; If subject is taking permitted concomitant medication(s), subject must have been on a stable dose and frequency of medication(s) over the past 28 days prior to the initiation of Screening; however, subjects taking niacin and resveratrol must have been on a stable dose and frequency for 90 days prior to the initiation of Screening; Subjects who are currently receiving omaveloxolone or intend to receive omaveloxolone are permitted in the study but must either receive CTI-1601 for 3 months prior to their first dose of omaveloxolone or receive omaveloxolone for 3 months prior to their first dose of CTI-1601.
Exclusion: Subject used any investigational drug (other than CTI-1601) or device within 90 days prior to Screening; Subject used erythropoietin, etravirine, or gamma interferon within 90 days prior to Screening; Subject use of biotin supplementation that exceeds 30 mcg/day, either as part of a multivitamin or as a standalone supplement, within 7 days prior to the first dose of study drug. Biotin supplementation ≤30 mcg/day is permitted if taken at a stable dose and frequency for at least 28 days prior to Screening and there is a commitment from the subject to maintain the biotin dose throughout the study (due to interference with assays); Subject receives medication that requires SC injection in the abdomen or thigh; Subject is unable to discontinue medications that have not been at a stable dose and frequency for at least 28 days prior to Screening; Subject has any condition, disease, or situation, including a cardiac condition or disease, that in the opinion of the PI, could confound the results of the study or put the subject at undue risk, making participation inadvisable; Subject has a Screening echocardiogram (ECHO) LVEF < 45%; Subjects are excluded from the study if any of the following exclusion criteria are met:; Subjects who are confirmed as compound heterozygous (GAA repeat expansion on only one allele) for FRDA; Subject requires use of amiodarone; Subject uses more than 3 grams of acetaminophen daily; Male subject has a QTcF > 450 milliseconds or female subject has a QTcF > 470 milliseconds on an ECG.